Read on Twitter
It has been a while since the company gave an update so I’m just reviewing my #NCYT investment thesis.
Key takeaways from recent updates:
1) Debt free, cash rich
Cash at 30 June was £18 million even after significant investment to meet demand and after paying down all debt
Key takeaways from recent updates:
1) Debt free, cash rich
Cash at 30 June was £18 million even after significant investment to meet demand and after paying down all debt
2) Strong demand, growing sales
Demand for the Company’s COVID-19 test remains strong, with June sales of £22.5 million showing the sixth consecutive month of growth. Certain contracts have also been extended into the second half of the year and in some cases into 2021
#NCYT
Demand for the Company’s COVID-19 test remains strong, with June sales of £22.5 million showing the sixth consecutive month of growth. Certain contracts have also been extended into the second half of the year and in some cases into 2021
#NCYT
3) USA partner securing significant sales
The Company has signed a major distribution agreement for its COVID-19 test with a new global strategic partner. The US is delivering significant sales growth for Novacyt
#NCYT
The Company has signed a major distribution agreement for its COVID-19 test with a new global strategic partner. The US is delivering significant sales growth for Novacyt
#NCYT
4) Launch of near patient testing
Launch of near-patient (mobile) testing, which we already know have been widely trialled by the NHS and in care homes
#NCYT
Launch of near-patient (mobile) testing, which we already know have been widely trialled by the NHS and in care homes
#NCYT
5) 2-gene test about to launch
To address markets employing this testing approach. Launch expected no later than September 2020.
This will be a sentiment changer for French investors.
#NCYT
To address markets employing this testing approach. Launch expected no later than September 2020.
This will be a sentiment changer for French investors.
#NCYT
6) Respiratory panel development
Development of a respiratory testing panel to diagnose and distinguish between influenza A&B, RSV and COVID-19.
We now know this is something the UK government is specifically looking for.
#NCYT
Development of a respiratory testing panel to diagnose and distinguish between influenza A&B, RSV and COVID-19.
We now know this is something the UK government is specifically looking for.
#NCYT
There are many other reasons (FDA SalivaDirect compatibility, directors buying at £3, antibody test development, etc.) but the ones above are key to showing where revenue is headed.
#NCYT will have made a new high before the end of 2020.
#NCYT will have made a new high before the end of 2020.
